MK-667, Geref, Trans-D tropin.

[monkeyballs]

Fellas,
So in planning for my upcoming GH/OX cycle, I've come across some forms of GHRH mimics that allegedly have similar effects to inj GH. These mimics stimulate the pit gland to secrete more GH (as much as 600% of the typical ammount), and so whatever gains that result are due to an increase in natural levels of GH. Thus far, I believe that there are three forms of this available, and one is still in development. One is a topical application called trans-D tropin made by balancederm (??????) and I believe it to be a scam. Some folks may disagree, but I wouldn't trust a pharm company that is only two years old and makes one product. The other two are injectables made by respectable labs. Geref made by serono, and MK-667 by merck. Both look promising. Mk-667 is still in development. I'll post the research that I found and let y'all ponder it over. Let me know what you guys think.


Here is the goods for Geref.

Most children with idiopathic (a disease of unknown origin or cause) growth hormone deficiency have an intact pituitary but it does not release adequate amounts of growth hormone. In these cases, Geref® (sermorelin acetate for injection), which is growth releasing factor therapy, may be the answer.
Geref® works to stimulate the pituitary to restore physiologic pulses of growth hormone (release endogenous growth hormone). Geref® doesn't replace growth hormone - it helps the body use its natural reserves. Geref® is the only physiologic choice to mimic the body's natural pattern of growth hormone release.

Geref® acts directly on the pituitary to stimulate synthesis and release of growth hormone.
 Secreted endogenous growth hormone acts on peripheral tissues.
 Tissues respond to GH & produce insulin-like growth factor 1 (IGF-1).
 IGF-1 stimulates the cells at the bone growth centers to divide, and this increases height.
Geref® Benefits
 Clinically proven effective. Children treated with Geref® (sermorelin acetate for injection) may increase their growth rate by more than 1 1/2 times during the first year of therapy. [Improvements of 4.1 ± 1.0 cm/yr to 7.2 ± 1.3 cm/yr were achieved in clinical trials with children.]
 Subcutaneous injection. Geref® is injected just below the skin with a very short, thin needle.
 Easy dosage. Injected once daily before bedtime, Geref® can easily become a part of your everyday routine.
Considerations:
 As with any drug, local or systemic allergic reactions may occur.
 If home use is prescribed, patients and/or their parents need to be instructed on the proper use and disposal of syringes and needles.
 The effect of Geref® therapy beyond one year and on final adult height remains to be determined.
 Patients who do not respond well to Geref® should be considered for treatment with growth hormone.

Serono Laboratories, Inc. launches Geref® Growth Hormone Releasing Hormone For Idiopathic GH Deficiency


NORWELL, MA -- April 27, 1998 – Serono Laboratories, Inc. has launched Geref® (sermorelin acetate for injection), the first growth hormone releasing hormone for the treatment of idiopathic growth hormone deficiency (GHD) in children and Geref® Diagnostic (sermorelin acetate for injection), a complementary product for the diagnosis of growth disorders in the United States. GHD results from either an abnormally low level of pituitary human growth hormone (hGH) or from a biochemical malfunction whereby growth hormone releasing hormone (GHRH) fails to trigger the release of hGH from the anterior pituitary. In the latter case, children with GHD may have endogenous hGH reserves which remain untapped.
As a growth hormone releasing hormone, Geref triggers the release of available reserves so that they can be used by the body. Traditionally, GHD has been treated by substituting natural hGH with a recombinant human growth hormone (r-hGH) product.
According to a study which appeared in the July 1994 Journal of Pediatrics, growth hormone deficiency, which inhibits skeletal growth, occurs in one out of every 3,500 children. Although GHD can be detected in infancy, most children who have the disorder are not diagnosed and treated until about age 10 -- a delay which clearly may prevent children from attaining their maximum growth potential. "It is widely believed that treatment should begin early for a child to reach his or her full growth potential, and there are some data to support the initiation of treatment before age five," said Michael Thorner, M.D., a leading expert on growth and chairman of the department of medicine at the University of Virginia Health Sciences Center.
In total, GHD affects an estimated 13,000 children in the U.S., according to the Human Growth Foundation.
Geref Diagnostic, is a tool for detecting the cause of a child's slow growth and can be used either prior to Geref treatment or as a stand-alone diagnostic agent. With currently available diagnostic tests, physicians are unable to differentiate between hypothalamic and pituitary dysfunction, both of which impact growth. By directly stimulating the pituitary to release growth hormone, Geref Diagnostic clarifies the source of slow growth and enables a more accurate diagnosis. While it is known that many children with GHD have natural growth hormone reserves, until now it has been impossible to distinguish them from those children who lack growth hormone or whose natural
supplies are inadequate."Geref and Geref Diagnostic add a new dimension to the diagnosis and treatment of GHD," Dr. Thorner said. "We will now be able to identify and more appropriately treat children whose GHD results from the body's failure to release hGH."Geref(R) (sermorelin acetate for injection) has demonstrated a favorable safety profile. The most common adverse reactions include local injection reactions (occurring in about one patient in six) characterized by pain, swelling or redness. During clinical trials, only three of 350 patients discontinued therapy due to injection reactions. Other treatment-related adverse events with occurrence rates of less than one percent include: headache, flushing, dysphagia, dizziness, hyperactivity, somnolence and urticaria.
A large portion of patients developed anti-GRF antibodies at least once during treatment with Geref. However, the significance of the antibodies is not clear. The presence of these antibodies does not appear to affect growth or be related to a specific adverse reaction profile and no generalized allergic reactions to Geref have been reported.
Adverse reactions reported with the use of Geref(R) Diagnostic (sermorelin acetate for injection), in decreasing order of frequency are: transient warmth and/or flushing of the face, injection site pain, redness and/or swelling at injection site, nausea, headache and vomiting. Approximately one in four patients given repeated doses of Geref Diagnostic has developed antibodies -- the clinical significance of these antibodies is unknown.

 

[monkeyballs]

And for the Trans-D tropin...
This research really sounds more like an ad than anything.


The Study
Trans-D Tropin naturally simulates the action of the hypothalamus to stimulate the pituitary to produce more of the bodies own endogenous HGH. We now have at our command what may be the ideal method of stimulating our own bodies natural HGH levels rapidly, effectively and without side effects.
It’s that simple. Please remember that Trans D Tropin is not GH. It imimicks GHRH and is recognized by the body as an endogenous form. It will directly result in the increase of endogenous GH. Trans-D Tropin is transdermal, it enters through the dermis. It should be applied to an area where there is minimal subcutaneous tissue with the highest vascular supply. The forearms are the best since the brachial musculature is adherent to the dermis with very little subcutaneous tissue to block the absorption. Trans-D Tropin has already begun to revolutionize the anti-aging field of medicine, as well as the sports supplementation industry. The result in athletes is nothing short of amazing. We welcome you to inquire about how you can provide this service to your patients and increase the net income of your practice. Trans-D Tropin is only available by prescription. It has been said that the purest and most absolute form of science is simple observation. We invite you to partake in this purest form of science and simply observe the difference in yourself after taking Trans-D Tropin. We are confident that you will be nothing short of impressed and excited about the potential impact that it will have on the welfare of your patients and your practice. A study conducted by Rashid A. Buttar, DO; Dean C. Viktora, PhD and Michael E. Quinn, EMT-P demonstrated accelerated and efficacious results using the variable somatotroph specific and hypothalamotroph specific polypeptide combinants in an isolated complex with naturally derived sources of IGF-1 precursors as an alternative to synthetic human growth hormone injections and oral growth hormone secretagogues. The patients chosen for the study were divided into two groups, the first comprising well trained, conditioned athletes and the second comprising average activity individuals older than 50 years of age. The well conditioned athletic group was chosen based upon level of physical fitness and a history of consistent high intensity athletic activity for a minimum of 12 consecutive months prior to onset of the study.All but 2 in this category were competitive power lifters, body builders, or professional athletes. All subjects had preliminary IGF-1 levels measured within the normal reference range for their respective ages. In addition, baseline chemistries with LFT’s, cholestrol and triglycerides were measured.The n number for this preliminary study was 18 with a total of 9 men and 9 women. A longer study of 6 weeks with an n of 100 plus has been initiated which will have the results of the IGF-1’s and chemistries drawn post study.The athletic group was included because attaining a rapid response in a trained and conditioned athlete would be a significantly more difficult outcome to achieve. This may be a result of the sustained higher levels of circulating hGH found in this patient population due to the exercise induced effects.The older group was selected since GH levels begin decreasing noticeably as we age. As previous studies have established, the level of circulating GH is not as important as establishing GH responsiveness to GHRH. The decrease of this responsiveness to GH as we age may be due to insufficient GHRH secretion or possibly by the inhibition of somatostatin a GH antagonist. It appears that this dysfunction at the pituitary hypothalamic axis is where the effects of Trans-D Tropin seem to be most apparent.All study subjects were provided with a detailed log sheet and required to document all changes in each criteria on a scale of -5 to +5 with 0 being no change and +5 being maximum improvement. Baseline for all criteria was zero at the initiation of the study. This methodology of assessment for a clinical study by ranking positive and negative changes on a +5 to -5 scale is an accepted modality of evaluation with previous studies having set the precedent. Study subjects applied a specified number of drops 3 times a day on the flexor surface of the forearms with a number of days off per week.Times of application corresponded to the natural release of GHRH in humans. All subjective data was recorded at 12 hour intervals with the total duration of this initial study being 84 hours or a total of 7 data samplings in less than a four day period.The subjective criteria that patients were required to record included the following: sense of well being, overall energy, mental clarity, emotional stability, memory improvement, mood improvement, skin thickness, skin elasticity, wrinkle disappearance, new hair growth, skin texture, healing of old injuries, healing of all injuries, range of motion, incidence of illness, body contour change, facial contour change, sexual frequency, sexual stamina, libido, quality of erection/arousal, and decrease in nighttime urination. The major objective criteria measured was muscle strength. Overall energy, exercise endurance and quality of sleep were also objectively measured.Lastly, to rule out or minimize placebo affect, the number of repetitions of the last set during exercise was used as a measurement of improvement as opposed to maximum lift capacity. Although all the study subjects dramatically increased their maximum lift capacities, the number of repetitions of the last set (performed at a higher weight) were deemed to be more significant since placebo effects are usually not reproducible. The logic used was that it would be difficult to attribute an increase in strength by 50 lbs in a specific exercise to a placebo effect when the exercise was performed for 10 to 12 repetitions.Results: A noticeable increase in all criteria monitored reveals the true benefits of increasing the effects of endogenous GH production and increasing GH responsiveness to GHRH. An important benefit associated with GH therapy and the reversal of the aging process is actually a sequelae of the natural up-regulation of all the various hormonal levels.
Total improvement per patient was summed and negative changes subtracted from the total per time period. This number represented the total sum of changes experienced by each individual study patient. The numbers generated representing each patient’s total net improvement were then combined to obtain a mean of all study patients per time period with the calculated values plotted by sex. The mean improvement measured by changes experienced by the study group from 12 hours post onset of study to 84 hours post onset of study increased substantially, with a 282.98 % change in female test subjects and 352.38 % change in male test subjects. Each data point represents two objectively measured quantitative criteria, specifically muscle strength and exercise endurance, as well as two qualitative objective criteria, specifically quality of sleep and overall energy. The data shows the mean improvement measured from 12 hours to 84 hours post onset of study to have also increased substantially. Changes were as follows: Muscle strength increased by 81.0%. Endurance increased by 60.0%. Quality of sleep improved by 92.6%. Overall energy increased by 71.4%. Total mean improvement of all 4 criteria increased by 76.6%. It is important to note that this percent change increase does not reflect the changes that became evident within the first 12 hours. In all the results were remarkable across the board for both groups.

 

[monkeyballs]

And lastly for the MK-667. It's all I could find...


http://www.cem.msu.edu/~cem181fp/sleep/part2.html
However, treatments with MK - 677 [Fig. 2] somehow stimulate the secretion of GH. For that reason, MK - 677 is called a
GH secretagogue -- a chemical that stimulates production/secretion of another substance. MK-677 is neither a hormone nor apeptide compound. It, however has been shown to increase GH levels and improve sleep quality for young boys and adults whentaken orally. Recent testing has shown that prolonged high dose treatments of MK-677 (25mg) resulted in a 20% increase inREM sleep for 18 to 30 year old adults and a 50% increase in REM sleep for older adults. These increases in sleep time wereaccompanied by larger pulses of GH secretion at the onset of sleep. Since MK-677was discovered so recently, there is a limitedamount of research on this drug. Testing is now taking place at Merck Laboratories. No side effects of the drug MK-677 areknown; only benefits. WOW. THAT'S NEAT. SO, UH, HOW DOES IT WORK? The mechanisms by which MK-677 operates are not completely understood at this time. However, a recent study has
identified a new receptor for GHRP and MK-677 in both the pituitary gland and the hypothalamus. This leads us to conclude thatMK-677 actually affects the central nervous system. It is also possible that MK-677, in addition to its power to increase in GH
secretion, simply has a favorable effect on the hormones that regulate sleep for the human body. In either case, it would be
advantageous to study the recently discovered receptor for GHRP and MK-677. The answers to many questions concerning
MK-677 lie in the understanding of this new receptor and its function. Further testing of MK-677 is necessary to look for
long-term side effects, for no short-term side effects have been discovered. But for now, MK-677 seems to be a miracle
treatment for decreased GH secretion as well as sleepless nights.

 

[PopiChulo]

Damn is it long enough?

 

[monkeyballs]

Sorry...but this post is only for the literate.

But thank you for your contribution.

 

[monkeyballs]

Gonna Bump so M.O.D. and Ironmaster have plenty of time to put on their bi-focals...and tell me what I already suspect- that most of this stuff is crap. One more thing about Geref, it's about twice as expensive as rGH and serono admits that the pituitary gland becomes desensitized to it's effects after several months of treatment. I imagine that the same goes for all the other GHRH mimics.

 

[monkeyballs]

one last bump.